You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

TRELEGY Ellipta – a simple medication routine1-4

ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonists

TRELEGY Ellipta provides appropriate patients with COPD, who need stepping up to triple therapy:

  • A combination of FF/UMEC/VI4
  • The benefit of a single daily inhalation4
  • All in an easy-to-use inhaler1-4

Life is complicated enough for patients with COPD

When patients have to remember how to use multiple different inhalers with different dosing frequencies, errors could arise. These may lead to poor inhaler technique, and worse COPD outcomes.5-7

This diagram does not represent all inhalers or all possible combinations. Ellipta, Diskus and the shape of the respective inhalers are registered trademarks of the GlaxoSmithKline Group of Companies. Other trademarks referred to herein are the property of their respective owners.

You can feel confident that patients are using the Ellipta inhaler correctly – compared to other commonly-used COPD inhalers1-3

It’s necessary to consider the inhalation technique of the patient, as inhalers are often used incorrectly.5 Poor inhalation technique, decreased medication delivery and suboptimal dosing can leave you unaware of how much they’ve taken and when.20 In fact, poor inhaler technique can be one of the reasons why COPD symptoms aren’t under control.5

Studies that assess and compare critical inhaler technique errors* can help determine the useful attributes of different COPD inhalers.1 Significantly fewer patients made a critical error when using the Ellipta inhaler, 2 3compared with other commonly used COPD inhalers.1

Ellipta, Diskus and the shape of the respective inhalers are registered trademarks of the GSK group of Companies.
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs.
1
This study assessed critical errors in the most common type of MDI (metered –dose inhaler) where shaking prior to use is required. The most common critical error with an MDI was poor actuation and inhalation coordination.1 Patients were naive to the inhalers they were assessed on. Patients were assessed on whether a critical error was made following reading the patient information leaflet for the inhaler.

TRELEGY Ellipta: An easy-to-use inhaler1 4 21

To use TRELEGY Ellipta, appropriate patients with COPD simply have to Open, Inhale, Close.4 21

Step 1: Open The patient slides the cover down until they hear a click. The dose counter counts down by 1, and the patient is ready to take one dose of their medicine.

Step 2: Inhale Exhale out. The patient puts their lips around the mouthpiece and takes a deep, slow breath in. The patient holds their breath for 3-4 seconds.

Step 3: Close Slide the cover upwards as far as it will go to cover the mouthpiece.

Please refer to the Patient Information Leaflet that comes with this pack for full instruction on using this inhaler.

Watch this video on how to use the Ellipta inhaler.

References:

  1. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26: 16079.
  2. Riley JH et al. Int J Chron Obstruct Pulmon Dis 2016; 11: 1873-80.
  3. Svesdsater H et al. BMC Pulm Med 2013; 13: 72.
  4. Trelegy Ellipta 92/55/22 SmPC, available at www.medicines.ie, accessed 14 March 2018.
  5. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2018.
  6. Melani AS et al. Respir Med 2011; 105:930–938.
  7. Bourbeau J, Bartlett SJ. Thorax 2008; 63:831–838.
  8. Incruse Ellipta 55 mcg SmPC, available at www.medicines.ie, accessed 14 March 2018.
  9. Relvar Ellipta 92/22 mcg SmPC, available at www.medicines.ie, accessed 14 March 2018.
  10. AirFluSal Forspiro Summary of Product Characteristics, 2017.
  11. Braltus Zonda Summary of Product Characteristics, 2016.
  12. Duoresp Spiromax Summary of Product Characteristics, 2017.
  13. Eklira Genuair Summary of Product Characteristics, 2017.
  14. Seebri Breezhaler Summary of Product Characteristics, 2016.
  15. Seretide Diskus Summary of Product Characteristics, 2017.
  16. Spiriva HandiHaler Summary of Product Characteristics, 2015.
  17. Spiriva Respimat Summary of Product Characteristics, 2016.
  18. Symbicort MDI Summary of Product Characteristics, 2017.
  19. Symbicort Turbohaler Summary of Product Characteristics, 2017.
  20. Pothirat C et al. Int J Chron Obstruct Pulmon Dis 2015 ; 10: 1291-8.

TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. 4

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

© 2018 GlaxoSmithKline Group of Companies. Trelegy and Ellipta are trademarks of the GlaxoSmithKline group of companies.